<?xml version="1.0" encoding="utf-8"?>
<quiz>
  <category id="2" title="CORE DEFECTS">
    <question id="1" qid="5">
      <copy><![CDATA[Insulin resistance can lead to beta-cell failure.]]></copy>
      <answer correct="1"><![CDATA[True]]></answer>
      <answer correct="0"><![CDATA[False]]></answer>
	  <drug><![CDATA[ACTOS]]></drug>
      <graphic>q5_image_01.jpg</graphic>
      <correctanswer><![CDATA[You're right! Increased insulin resistance can lead to beta-cell dysfunction and affect the body's ability to maintain healthy glucose levels.<FONT FACE="GG Superscript">1</FONT> In fact, insulin resistance and loss of beta-cell function may begin as early as 10−12 years prior to diagnosis.<FONT FACE="GG Superscript">2-4</FONT>]]></correctanswer>
      <incorrectanswer><![CDATA[Not quite. Increased insulin resistance can lead to beta-cell dysfunction and affect the body's ability to maintain healthy glucose levels.<FONT FACE="GG Superscript">1</FONT> In fact, insulin resistance and loss of beta-cell function may begin as early as 10−12 years prior to diagnosis.<FONT FACE="GG Superscript">2-4</FONT>]]></incorrectanswer>
      <annotations>
        <notation id="1" title="footnote"><![CDATA[]]></notation>
        <notation id="2" title="references"><![CDATA[<b>1.</b> Bailey CJ. Insulin resistance and antidiabetic drugs. <i>Biochem Pharmacol.</i> 1999;58:1511-1520. <b>2.</b> Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. <i>Diabetes.</i> 1996;45:1661-1669. <b>3.</b> Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4−7 yr before clinical diagnosis. <i>Diabetes Care.</i> 1992;15:815-819.<br><b>4.</b> Holman RR. Assessing the potential for <FONT FACE="Times New Roman" SIZE="16">α</FONT>-glucosidase inhibitors in prediabetic states. <i>Diabetes Res Clin Pract.</i> 1998;40(suppl):S21-S25. <b>5.</b> Bailey CJ. Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones. <i>Diabetes Obes Metab.</i> 2005;7:675-691.<br><b>6.</b> American Heart Association website. Insulin resistance. Available at: http://www.americanheart.org/presenter.jhtml?identifier=3044761. Accessed June 2, 2008. <br><b>7.</b> ACTOS package insert, Takeda Pharmaceuticals America, Inc.]]></notation>
        <notation id="3" title="fairbalance"><![CDATA[Management of type 2 diabetes should also include nutritional counseling, weight reduction as needed, and exercise.<br><br>Please see Important Safety Information, <b>including boxed warnings</b>, by clicking on the Safety button in the Menu.]]></notation>
        <notation id="4" title="indication"><![CDATA[ACTOS is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. ACTOS is approved for use as monotherapy and in combination with sulfonylureas, metformin, or insulin when diet and exercise plus the single agent do not result in adequate glycemic control.<FONT FACE="GG Superscript">7</FONT>]]></notation>
      </annotations>
      <complexityfactor>1</complexityfactor>
    </question>
    <question id="2" qid="6">
      <copy><![CDATA[Beta-cell dysfunction is the only defect of type 2 diabetes.]]></copy>
      <answer correct="0"><![CDATA[True]]></answer>
      <answer correct="1"><![CDATA[False]]></answer>
	  <drug><![CDATA[ACTOS]]></drug>
      <graphic></graphic>
      <correctanswer><![CDATA[Myriad factors contribute to the pathogenesis of type 2 diabetes; chief among them are beta-cell dysfunction, increased hepatic glucose output, and increased insulin resistance.<FONT FACE="GG Superscript">1</FONT>]]></correctanswer>
      <incorrectanswer><![CDATA[Actually, that's only partly correct. Myriad factors contribute to the pathogenesis of type 2 diabetes; chief among them are beta-cell dysfunction, increased hepatic glucose output, and increased insulin resistance.<FONT FACE="GG Superscript">1</FONT>]]></incorrectanswer>
      <annotations>
        <notation id="1" title="footnote"><![CDATA[]]></notation>
        <notation id="2" title="references"><![CDATA[<b>1.</b> Schinner S, Scherbaum WA, Bornstein SR, Barthel A. Molecular mechanisms of insulin resistance. <i>Diabet Med.</i> 2005;22:674-682. <b>2.</b> ACTOS package insert, Takeda Pharmaceuticals America, Inc.]]></notation>
        <notation id="3" title="fairbalance"><![CDATA[Management of type 2 diabetes should also include nutritional counseling, weight reduction as needed, and exercise.<br><br>Please see Important Safety Information, <b>including boxed warnings</b>, by clicking on the Safety button in the Menu.]]></notation>
        <notation id="4" title="indication"><![CDATA[ACTOS is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. ACTOS is approved for use as monotherapy and in combination with sulfonylureas, metformin, or insulin when diet and exercise plus the single agent do not result in adequate glycemic control.<FONT FACE="GG Superscript">2</FONT>]]></notation>
      </annotations>
      <complexityfactor>1</complexityfactor>
    </question>
    <question id="3" qid="7">
      <copy><![CDATA[Insulin resistance is often associated with abnormalities that impact which of the following?]]></copy>
      <answer correct="0"><![CDATA[Lipid metabolism]]></answer>
      <answer correct="0"><![CDATA[Protein metabolism]]></answer>
      <answer correct="0"><![CDATA[Gene expression]]></answer>
      <answer correct="1"><![CDATA[All of the above]]></answer>
	  <drug><![CDATA[ACTOS]]></drug>
      <graphic>q7_image_01.jpg</graphic>
      <correctanswer><![CDATA[You're right! Insulin resistance is often associated with lipid and protein abnormalities, as well as cardiovascular function and gene expression abnormalities.<FONT FACE="GG Superscript">1</FONT> Insulin resistance in the periphery can lead to insufficient beta-cell function and elevated glucose levels.<FONT FACE="GG Superscript">2</FONT> Left untreated, insulin resistance continues, and other complications may develop over time.<FONT FACE="GG Superscript">3</FONT>]]></correctanswer>
      <incorrectanswer><![CDATA[Actually, insulin resistance is often associated with lipid and protein abnormalities, as well as cardiovascular function and gene expression abnormalities.<FONT FACE="GG Superscript">1</FONT> Insulin resistance in the periphery can lead to insufficient beta-cell function and elevated glucose levels.<FONT FACE="GG Superscript">2</FONT> Left untreated, insulin resistance continues, and other complications may develop over time.<FONT FACE="GG Superscript">3</FONT>]]></incorrectanswer>
      <annotations>
        <notation id="1" title="footnote"><![CDATA[]]></notation>
        <notation id="2" title="references">
          <![CDATA[<b>1.</b> American Diabetes Association. Consensus development conference on insulin resistance. <i>Diabetes Care.</i>1998;21:310-314. <b>2.</b> DeFronzo RA. The triumvirate: ß-cell, muscle, liver: a collusion responsible for NIDDM [Lilly Lecture 1987]. <i>Diabetes.</i> 1988;37:667-687. <b>3.</b> Nesto RW. The relation of insulin resistance syndromes to risk of cardiovascular disease. <i>Rev Cardiovasc Med.</i> 2003;4(suppl 6):S11-S18. <b>4.</b> Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic ß-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. <i>Diabetes.</i> 2002;51:2796-2803. <b>5.</b> Hsueh WA, Law RE. Cardiovascular risk continuum: implications of insulin resistance and diabetes. <i>Am J Med.</i> 1998;105:4S-14S. <b>6.</b> National Diabetes Information Clearinghouse (NDIC) website. Diabetes, heart disease, and stroke. Available at: http://www.diabetes.niddk.nih.gov/dm/pubs/stroke. Accessed June 2, 2008. <b>7.</b> American Diabetes Association website. Diabetes: heart disease and stroke. Available at: http://www.diabetes.org/diabetes-heart-disease-stroke.jsp. Accessed June 2, 2008. <b>8.</b> Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. <i>Diabetes.</i> 1996;45:1661-1669. <b>9.</b> ACTOS package insert, Takeda Pharmaceuticals America, Inc.]]>
        </notation>
        <notation id="3" title="fairbalance"><![CDATA[Management of type 2 diabetes should also include nutritional counseling, weight reduction as needed, and exercise.<br><br>Please see Important Safety Information, <b>including boxed warnings</b>, by clicking on the Safety button in the Menu.]]></notation>
        <notation id="4" title="indication"><![CDATA[ACTOS is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. ACTOS is approved for use as monotherapy and in combination with sulfonylureas, metformin, or insulin when diet and exercise plus the single agent do not result in adequate glycemic control.<FONT FACE="GG Superscript">9</FONT>]]></notation>
      </annotations>
      <complexityfactor>1</complexityfactor>
    </question>
    <question id="4" qid="8">
      <copy><![CDATA[By the time patients are diagnosed with type 2 diabetes, beta-cell function has typically declined by an average of 50%.]]></copy>
      <answer correct="1"><![CDATA[True]]></answer>
      <answer correct="0"><![CDATA[False]]></answer>
	  <drug><![CDATA[ACTOS]]></drug>
      <graphic></graphic>
      <correctanswer><![CDATA[Yes! Typically, beta-cell function has declined by an average of 50% by the time patients are diagnosed with type 2 diabetes.<FONT FACE="GG Superscript">1,2</FONT> Despite treatment with sulfonylurea or metformin monotherapy, patients continue to experience a decline in beta-cell function over time.<FONT FACE="GG Superscript">1</FONT> Declining beta-cell function is associated with loss of glycemic control.<FONT FACE="GG Superscript">1</FONT>]]></correctanswer>
      <incorrectanswer><![CDATA[That's not correct. Typically, beta-cell function has declined by an average of 50% by the time patients are diagnosed with type 2 diabetes.<FONT FACE="GG Superscript">1,2</FONT> Despite treatment with sulfonylurea or metformin monotherapy, patients continue to experience a decline in beta-cell function over time.<FONT FACE="GG Superscript">1</FONT> Declining beta-cell function is associated with loss of glycemic control.<FONT FACE="GG Superscript">1</FONT>]]></incorrectanswer>
      <annotations>
        <notation id="1" title="footnote"><![CDATA[]]></notation>
        <notation id="2" title="references"><![CDATA[<b>1.</b> UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 16: overview of 6 years' therapy of type II diabetes: a progressive disease. <i>Diabetes.</i> 1995;44:1249-1258.<br><b>2.</b> Lebovitz HE. Insulin secretagogues: old and new. <i>Diabetes Rev.</i> 1999;7:139-153.<br><b>3.</b> ACTOS package insert, Takeda Pharmaceuticals America, Inc.]]></notation>
        <notation id="3" title="fairbalance"><![CDATA[Management of type 2 diabetes should also include nutritional counseling, weight reduction as needed, and exercise.<br><br>Please see Important Safety Information, <b>including boxed warnings</b>, by clicking on the Safety button in the Menu.]]></notation>
        <notation id="4" title="indication"><![CDATA[ACTOS is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. ACTOS is approved for use as monotherapy and in combination with sulfonylureas, metformin, or insulin when diet and exercise plus the single agent do not result in adequate glycemic control.<FONT FACE="GG Superscript">3</FONT>]]></notation>
      </annotations>
      <complexityfactor>1</complexityfactor>
    </question>
  </category>
  <category id="1" title="TARGETING DEFECTS">
    <question id="1" qid="4">
      <copy><![CDATA[What percentage of patients with type 2 diabetes have insulin resistance?]]></copy>
      <answer correct="0"><![CDATA[100%]]></answer>
      <answer correct="1"><![CDATA[92%]]></answer>
      <answer correct="0"><![CDATA[82%]]></answer>
	  <drug><![CDATA[ACTOS]]></drug>
      <graphic></graphic>
      <correctanswer><![CDATA[That's right! 92% of patients with type 2 diabetes have insulin resistance.<FONT FACE="GG Superscript">1</FONT> Insulin resistance and loss of beta-cell function may begin as early as 10−12 years before diagnosis.<FONT FACE="GG Superscript">2-4</FONT>]]></correctanswer>
      <incorrectanswer><![CDATA[Close, but not quite. 92% of patients with type 2 diabetes have insulin resistance.<FONT FACE="GG Superscript">1</FONT> Insulin resistance and loss of beta-cell function may begin as early as 10−12 years before diagnosis.<FONT FACE="GG Superscript">2-4</FONT>]]></incorrectanswer>
      <annotations>
        <notation id="1" title="footnote"><![CDATA[]]></notation>
        <notation id="2" title="references"><![CDATA[<b>1.</b> Haffner SM, D’Agostino R Jr, Mykkänen L, et al. Insulin sensitivity in subjects with type 2 diabetes: relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. <i>Diabetes Care.</i> 1999;22:562-568. <b>2.</b> Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. <i>Diabetes.</i> 1996;45:1661-1669. <b>3.</b> Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4−7 yr before clinical diagnosis. <i>Diabetes Care.</i> 1992;15:815-819. <b>4.</b> Holman RR. Assessing the potential for <br><FONT FACE="Times New Roman" SIZE="16">α</FONT>-glucosidase inhibitors in prediabetic states. <i>Diabetes Res Clin Pract.</i> 1998;40(suppl):S21-S25.<br><b>5.</b> ACTOS package insert, Takeda Pharmaceuticals America, Inc.]]></notation>
        <notation id="3" title="fairbalance"><![CDATA[Management of type 2 diabetes should also include nutritional counseling, weight reduction as needed, and exercise.<br><br>Please see Important Safety Information, <b>including boxed warnings</b>, by clicking on the Safety button in the Menu.]]></notation>
        <notation id="4" title="indication"><![CDATA[ACTOS is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. ACTOS is approved for use as monotherapy and in combination with sulfonylureas, metformin, or insulin when diet and exercise plus the single agent do not result in adequate glycemic control.<FONT FACE="GG Superscript">5</FONT>]]></notation>
      </annotations>
      <complexityfactor>1</complexityfactor>
    </question>  
    <question id="2" qid="1">
      <copy><![CDATA[In addition to reducing A1C levels, what other effect(s) has ACTOS demonstrated in a 26-week clinical trial?]]></copy>
      <answer correct="0"><![CDATA[Reduction in insulin resistance]]></answer>
      <answer correct="0"><![CDATA[Improvement in beta-cell function (HOMA)]]></answer>
      <answer correct="1"><![CDATA[Both a & b]]></answer>
	  <drug><![CDATA[ACTOS]]></drug>
      <graphic>q1_image_01.jpg</graphic>
      <correctanswer><![CDATA[That's right! ACTOS reduced insulin resistance by 27% and improved beta-cell function by 40%.*<FONT FACE="GG Superscript">1-5</FONT> ACTOS targets multiple core defects of type 2 diabetes and improves glycemic control by an average of 2.6 percentage points in drug-naïve patients.*<FONT FACE="GG Superscript">6</FONT>]]></correctanswer>
      <incorrectanswer>
        <![CDATA[ACTOS does more than that. ACTOS reduced insulin resistance by 27% and improved beta-cell function by 40%.*<FONT FACE="GG Superscript">1-5</FONT> ACTOS targets multiple core defects of type 2 diabetes and improves glycemic control by an average of 2.6 percentage points in drug-naïve patients.*<FONT FACE="GG Superscript">6</FONT>]]>
      </incorrectanswer>
      <annotations>
        <notation id="1" title="footnote"><![CDATA[*Results from a 26-week, double-blind, randomized, multicenter, placebo-controlled study. HOMA is based on the following calculations: HOMA−IR = (fasting insulin x fasting glucose)/22.5; HOMA−BCF = (20 x fasting insulin)/(fasting glucose −3.5). Values indicate the difference between the changes from baseline of ACTOS and placebo. <br><br>A1C data: drug-naïve patients not adequately controlled by diet and exercise alone and receiving ACTOS 45 mg QD, n=21, baseline A1C: 10.0%. <i>P</i>≤0.05.]]></notation>
        <notation id="2" title="references"><![CDATA[<b>1.</b> Data on file, Takeda Pharmaceuticals North America, Inc. <b>2.</b> ACTOS package insert, Takeda Pharmaceuticals America, Inc. <b>3.</b> Miyazaki Y, Matsuda M, DeFronzo RA. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. <i>Diabetes Care.</i> 2002;25:517-523. <b>4.</b> Miyazaki Y, Mahankali A, Matsuda M, et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. <i>Diabetes Care.</i> 2001;24:710-719. <b>5.</b> Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and ß-cell function from fasting plasma glucose and insulin concentrations in man. <i>Diabetologia.</i> 1985;28:412-419. <b>6.</b> Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL, and the Pioglitazone 001 Study Group. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. <i>Diabetes Care.</i> 2000;23:1605-1611.]]></notation>
        <notation id="3" title="fairbalance"><![CDATA[Management of type 2 diabetes should also include nutritional counseling, weight reduction as needed, and exercise.<br><br>Please see Important Safety Information, <b>including boxed warnings</b>, by clicking on the Safety button in the Menu.]]></notation>
        <notation id="4" title="indication"><![CDATA[ACTOS is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. ACTOS is approved for use as monotherapy and in combination with sulfonylureas, metformin, or insulin when diet and exercise plus the single agent do not result in adequate glycemic control.<FONT FACE="GG Superscript">2</FONT>]]></notation>
      </annotations>
      <complexityfactor>1</complexityfactor>
    </question>
    <question id="3" qid="2">
      <copy><![CDATA[ACTOS targets which defects of type 2 diabetes?]]></copy>
      <answer correct="0"><![CDATA[Insulin resistance]]></answer>
      <answer correct="0"><![CDATA[Hepatic glucose output]]></answer>
      <answer correct="0"><![CDATA[Beta-cell dysfunction]]></answer>
      <answer correct="1"><![CDATA[All of the above]]></answer>
	  <drug><![CDATA[ACTOS]]></drug>
      <graphic>q2_image_01.jpg</graphic>
      <correctanswer><![CDATA[That's right! ACTOS targets insulin resistance, hepatic glucose output, and beta-cell dysfunction.<FONT FACE="GG Superscript">1,2</FONT> Specifically, ACTOS sustains glycemic control by decreasing hepatic glucose output, decreasing insulin resistance, and improving beta-cell function. Beta-cell function is measured according to HOMA (Homeostasis Model Assessment).<FONT FACE="GG Superscript">1,3-5</FONT>]]></correctanswer>
      <incorrectanswer><![CDATA[ACTOS does more than that. ACTOS targets insulin resistance, hepatic glucose output, and beta-cell dysfunction.<FONT FACE="GG Superscript">1,2</FONT> Specifically, ACTOS sustains glycemic control by decreasing hepatic glucose output, decreasing insulin resistance, and improving beta-cell function. Beta-cell function is measured according to HOMA (Homeostasis Model Assessment).<FONT FACE="GG Superscript">1,3-5</FONT>]]></incorrectanswer>
      <annotations>
        <notation id="1" title="footnote"><![CDATA[]]></notation>
        <notation id="2" title="references">
          <![CDATA[<b>1.</b> ACTOS package insert, Takeda Pharmaceuticals America, Inc. <b>2.</b> Miyazaki Y, Matsuda M, DeFronzo RA. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. <i>Diabetes Care.</i> 2002;25:517-523. <b>3.</b> Kendall DM. Thiazolidinediones: the case for early use. <i>Diabetes Care.</i> 2006;29:154-157. <b>4.</b> Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR, Fonseca VA. Nonhypoglycemic effects of thiazolidinediones. <i>Ann Intern Med.</i> 2001;134:61-71. <b>5.</b> Del Prato S, Marchetti P. Targeting insulin resistance and ß-cell dysfunction: the role of thiazolidinediones. <i>Diabetes Technol Ther.</i> 2004;6:719-731.
]]>
        </notation>
        <notation id="3" title="fairbalance"><![CDATA[Management of type 2 diabetes should also include nutritional counseling, weight reduction as needed, and exercise.<br><br>Please see Important Safety Information, <b>including boxed warnings</b>, by clicking on the Safety button in the Menu.]]></notation>
        <notation id="4" title="indication"><![CDATA[ACTOS is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. ACTOS is approved for use as monotherapy and in combination with sulfonylureas, metformin, or insulin when diet and exercise plus the single agent do not result in adequate glycemic control.<FONT FACE="GG Superscript">1</FONT>]]></notation>
      </annotations>
      <complexityfactor>1</complexityfactor>
    </question>
    <question id="4" qid="3">
      <copy><![CDATA[What benefits can be achieved by targeting insulin resistance with ACTOS?]]></copy>
      <answer correct="0"><![CDATA[Improvement in hyperglycemia]]></answer>
      <answer correct="0"><![CDATA[Decrease in circulating insulin levels]]></answer>
      <answer correct="0"><![CDATA[Improvement in beta-cell function (HOMA)]]></answer>
      <answer correct="0"><![CDATA[Improvement in diabetic dyslipidemia]]></answer>
      <answer correct="1"><![CDATA[All of the above]]></answer>
	  <drug><![CDATA[ACTOS]]></drug>
      <graphic></graphic>
      <correctanswer>
        <![CDATA[You know the benefits of ACTOS. Targeting insulin resistance with ACTOS can have many benefits: ACTOS can have an effect on several cardiovascular risk markers, such as hyperglycemia, hyperinsulinemia, and diabetic dyslipidemia.<FONT FACE="GG Superscript">1</FONT><br><br>ACTOS can also decrease circulating insulin levels and improve beta-cell function (HOMA).<FONT FACE="GG Superscript">2-4</FONT><br><br>No consistent mean changes in LDL-C or Total-C levels have occurred with ACTOS.<FONT FACE="GG Superscript">4</FONT>]]>
      </correctanswer>
      <incorrectanswer><![CDATA[Actually…Targeting insulin resistance with ACTOS can have many benefits: ACTOS can have an effect on several cardiovascular risk markers, such as hyperglycemia, hyperinsulinemia, and diabetic dyslipidemia.<FONT FACE="GG Superscript">1</FONT><br><br>ACTOS can also decrease circulating insulin levels and improve beta-cell function (HOMA).<FONT FACE="GG Superscript">2-4</FONT><br><br>No consistent mean changes in LDL-C or Total-C levels have occurred with ACTOS.<FONT FACE="GG Superscript">4</FONT>]]></incorrectanswer>
      <annotations>
        <notation id="1" title="footnote"><![CDATA[]]></notation>
        <notation id="2" title="references"><![CDATA[<b>1.</b> Martens FC, Visseren FJ, Lemay J, de Koning EP, Rabelink TJ. Metabolic and additional vascular effects of thiazolidinediones. <i>Drugs.</i> 2002;62:1463-1480. <b>2.</b> Wyne KL, Bell DH, Braunstein S, Drexler AJ, Miller JL, Nuckolls JG. Trends in management of type 2 diabetes: role of thiazolidinediones. <i>Endocrinologist.</i> 2003;13(suppl 1):S1-S21. <b>3.</b> Reasner CA. Where thiazolidinediones will fit. <i>Diabetes Metab Res Rev.</i> 2002;18(suppl 2):S30-S35. <b>4.</b> ACTOS package insert, Takeda Pharmaceuticals America, Inc.]]></notation>
        <notation id="3" title="fairbalance"><![CDATA[While ACTOS may confer some lipid benefits, ACTOS is not indicated to treat lipid disorders and should not be used as a substitute for lipid-lowering therapy.<br><br>The effects of these lipid changes on morbidity and mortality have not been determined.<br><br>Management of type 2 diabetes should also include nutritional counseling, weight reduction as needed, and exercise.<br><br>Please see Important Safety Information, <b>including boxed warnings</b>, by clicking on the Safety button in the Menu.]]></notation>
        <notation id="4" title="indication"><![CDATA[ACTOS is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. ACTOS is approved for use as monotherapy and in combination with sulfonylureas, metformin, or insulin when diet and exercise plus the single agent do not result in adequate glycemic control.<FONT FACE="GG Superscript">4</FONT>]]></notation>
      </annotations>
      <complexityfactor>1</complexityfactor>
    </question>
  </category>
  <category id="3" title="A1C">
    <question id="1" qid="10">
      <copy><![CDATA[According to National Health and Nutrition Examination Survey (NHANES) data for 2003–2004, what percentage<br>of patients with diabetes are not getting to an A1C goal of &lt;7.0%?]]></copy>
      <answer correct="0"><![CDATA[15%]]></answer>
      <answer correct="0"><![CDATA[24%]]></answer>
      <answer correct="1"><![CDATA[44%]]></answer>
	  <drug><![CDATA[ACTOS]]></drug>
      <graphic>q10_image_01.jpg</graphic>
      <correctanswer><![CDATA[That's correct. Although A1C levels have been decreasing recently, 44% of patients were not at goal at the time of this survey. NHANES is a nationally representative, population-based survey, designed to collect health and nutrition information on the noninstitutionalized US population.<FONT FACE="GG Superscript">1</FONT>]]></correctanswer>
      <incorrectanswer><![CDATA[The number is actually higher. Although A1C levels have been decreasing recently, 44% of patients were not at goal at the time of this survey. NHANES is a nationally representative, population-based survey, designed to collect health and nutrition information on the noninstitutionalized US population.<FONT FACE="GG Superscript">1</FONT>]]></incorrectanswer>
      <annotations>
        <notation id="1" title="footnote"><![CDATA[]]></notation>
        <notation id="2" title="references"><![CDATA[<b>1.</b> Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in US adults? <i>Diabetes Care.</i> 2008;31:81-86. <b>2.</b> ACTOS package insert, Takeda Pharmaceuticals America, Inc.]]></notation>
        <notation id="3" title="fairbalance"><![CDATA[Management of type 2 diabetes should also include nutritional counseling, weight reduction as needed, and exercise.<br><br>Please see Important Safety Information, <b>including boxed warnings</b>, by clicking on the Safety button in the Menu.]]></notation>
        <notation id="4" title="indication"><![CDATA[ACTOS is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. ACTOS is approved for use as monotherapy and in combination with sulfonylureas, metformin, or insulin when diet and exercise plus the single agent do not result in adequate glycemic control.<FONT FACE="GG Superscript">2</FONT>]]></notation>
      </annotations>
      <complexityfactor>1</complexityfactor>
    </question>
    <question id="2" qid="11">
      <copy><![CDATA[According to the UK Prospective Diabetes Study (UKPDS) Group, what percentage of overweight patients on metformin monotherapy maintained an A1C goal of &lt;7.0% after 9 years?]]></copy>
      <answer correct="1"><![CDATA[13%]]></answer>
      <answer correct="0"><![CDATA[26%]]></answer>
      <answer correct="0"><![CDATA[52%]]></answer>
	  <drug><![CDATA[ACTOS]]></drug>
      <graphic></graphic>
      <correctanswer><![CDATA[Way to go! Only 13% of overweight patients on metformin were able to maintain the ADA-recommended A1C goal of &lt;7.0% after 9 years. Likewise, just 44% of patients on metformin monotherapy maintained their A1C goal of &lt;7.0% after 3 years; even fewer patients (34%) maintained that goal after 6 years of metformin monotherapy.<FONT FACE="GG Superscript">1</FONT>]]></correctanswer>
      <incorrectanswer><![CDATA[Not quite. Only 13% of overweight patients on metformin were able to maintain the ADA-recommended A1C goal of &lt;7.0% after 9 years. Likewise, just 44% of patients on metformin monotherapy maintained their A1C goal of &lt;7.0% after 3 years; even fewer patients (34%) maintained that goal after 6 years of metformin monotherapy.<FONT FACE="GG Superscript">1</FONT>]]></incorrectanswer>
      <annotations>
        <notation id="1" title="footnote"><![CDATA[]]></notation>
        <notation id="2" title="references"><![CDATA[<b>1.</b> Turner RC, Cull CA, Frighi V, Holman RR, for the UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). <i>JAMA.</i> 1999;281:2005-2012. <b>2.</b> ACTOS package insert, Takeda Pharmaceuticals America, Inc.]]></notation>
        <notation id="3" title="fairbalance"><![CDATA[Management of type 2 diabetes should also include nutritional counseling, weight reduction as needed, and exercise.<br><br>Please see Important Safety Information, <b>including boxed warnings</b>, by clicking on the Safety button in the Menu.]]></notation>
        <notation id="4" title="indication"><![CDATA[ACTOS is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. ACTOS is approved for use as monotherapy and in combination with sulfonylureas, metformin, or insulin when diet and exercise plus the single agent do not result in adequate glycemic control.<FONT FACE="GG Superscript">2</FONT>]]></notation>
      </annotations>
      <complexityfactor>1</complexityfactor>
    </question>
    <question id="3" qid="12">
      <copy><![CDATA[ACTOS 45 mg QD has been shown to reduce A1C by a mean of 2.6 percentage points in drug-naïve patients.]]></copy>
      <answer correct="1"><![CDATA[True]]></answer>
      <answer correct="0"><![CDATA[False]]></answer>
	  <drug><![CDATA[ACTOS]]></drug>
      <graphic>q12_image_01.jpg</graphic>
      <correctanswer><![CDATA[You know ACTOS well! In a clinical trial with drug-naïve patients with type 2 diabetes, ACTOS 45 mg QD reduced mean A1C by 2.6 percentage points vs placebo.*<FONT FACE="GG Superscript">1</FONT><br><br>In this same study across all patients, ACTOS 45 mg QD reduced mean A1C by 1.6 percentage points vs placebo.*<FONT FACE="GG Superscript">1</FONT>]]></correctanswer>
      <incorrectanswer><![CDATA[Actually, in a clinical trial with drug-naïve patients with type 2 diabetes, ACTOS 45 mg QD reduced mean A1C by 2.6 percentage points vs placebo.*<FONT FACE="GG Superscript">1</FONT><br><br>In this same study across all patients, ACTOS 45 mg QD reduced mean A1C by 1.6 percentage points vs placebo.*<FONT FACE="GG Superscript">1</FONT>]]></incorrectanswer>
      <annotations>
        <notation id="1" title="footnote"><![CDATA[*Results from a 26-week, double-blind, randomized, multicenter, placebo-controlled study. A1C data: patients not previously treated with diabetes medications and not adequately controlled by diet and exercise alone and receiving ACTOS 45 mg QD, n=21, baseline A1C: 10.0%. Across all patients receiving ACTOS 45 mg QD, n=76, baseline A1C: 10.3% (<i>P</i>≤0.05).]]></notation>
        <notation id="2" title="references"><![CDATA[<b>1.</b> Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL, and the Pioglitazone 001 Study Group. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. <i>Diabetes Care.</i> 2000;23:1605-1611. <b>2.</b> ACTOS package insert, Takeda Pharmaceuticals America, Inc. ]]></notation>
        <notation id="3" title="fairbalance"><![CDATA[Management of type 2 diabetes should also include nutritional counseling, weight reduction as needed, and exercise.<br><br>Please see Important Safety Information, <b>including boxed warnings</b>, by clicking on the Safety button in the Menu.]]></notation>
        <notation id="4" title="indication"><![CDATA[ACTOS is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. ACTOS is approved for use as monotherapy and in combination with sulfonylureas, metformin, or insulin when diet and exercise plus the single agent do not result in adequate glycemic control.<FONT FACE="GG Superscript">2</FONT>]]></notation>
      </annotations>
      <complexityfactor>1</complexityfactor>
    </question>
  </category>
  <category id="4" title="A1C_2">	
    <question id="1" qid="13">
      <copy><![CDATA[Compared with metformin alone, ACTO<i>plus</i> met reduces A1C by how many additional percentage points?]]></copy>
      <answer correct="1"><![CDATA[1.0]]></answer>
      <answer correct="0"><![CDATA[2.0]]></answer>
      <answer correct="0"><![CDATA[3.0]]></answer>
	  <drug><![CDATA[ACTOPLUSMET]]></drug>
      <graphic>q13_image_01.jpg</graphic>
      <correctanswer><![CDATA[You've got it! An additional 1.0 percentage point mean reduction in A1C was achieved with ACTO<i>plus</i> met.* A1C reductions with ACTO<i>plus</i> met were sustained beyond 2.5 years.<FONT FACE="GG Superscript">1,2</FONT>]]></correctanswer>
      <incorrectanswer><![CDATA[You're close, but... an additional 1.0 percentage point mean reduction in A1C was achieved with ACTO<i>plus</i> met.* A1C reductions with ACTO<i>plus</i> met were sustained beyond 2.5 years.<FONT FACE="GG Superscript">1,2</FONT>]]></incorrectanswer>
      <annotations>
        <notation id="1" title="footnote"><![CDATA[*Results from a 24-week, double-blind, randomized, multicenter study. Mean change statistically significant vs baseline at <i>P</i>≤0.05. ACTOS 45 mg baseline A1C: 9.8%, n=416.]]></notation>
        <notation id="2" title="references"><![CDATA[<b>1.</b> Data on file, Takeda Pharmaceuticals North America, Inc. <b>2.</b> ACTO<i>plus</i> met package insert, Takeda Pharmaceuticals North America, Inc.]]></notation>
        <notation id="3" title="fairbalance"><![CDATA[Management of type 2 diabetes should also include nutritional counseling, weight reduction as needed, and exercise.<br><br>Please see Important Safety Information, <b>including boxed warnings</b>, by clicking on the Safety button in the Menu.]]></notation>
        <notation id="4" title="indication"><![CDATA[ACTO<i>plus</i> met is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes who are already treated with a combination of pioglitazone and metformin, or whose diabetes is not adequately controlled with metformin alone, or for those patients who have initially responded to pioglitazone alone and require additional glycemic control.<FONT FACE="GG Superscript">2</FONT>]]></notation>
      </annotations>
      <complexityfactor>1</complexityfactor>
    </question>
    <question id="2" qid="14">
      <copy><![CDATA[When it comes to A1C reductions, how does <i>duet</i>act compare with a sulfonylurea alone?]]></copy>
      <answer correct="0"><![CDATA[Both treatments reduce A1C by the same number of percentage points]]></answer>
      <answer correct="0"><![CDATA[With <i>duet</i>act, patients achieve an additional 1.0 percentage point mean reduction in A1C vs a sulfonylurea alone]]></answer>
      <answer correct="1"><![CDATA[<i>Duet</i>act has been shown to provide patients an additional 1.6 percentage point mean reduction in A1C vs a sulfonylurea alone<br><br>]]></answer>
      <drug><![CDATA[DUETACT]]></drug>
	  <graphic>q14_image_01.jpg</graphic>
      <correctanswer><![CDATA[Yes! Patients taking <i>duet</i>act had an additional 1.6 percentage point mean reduction in A1C levels compared with those on a sulfonylurea alone.*<FONT FACE="GG Superscript">1,2</FONT> A1C reductions were sustained out to 2 years.<FONT FACE="GG Superscript">3</FONT>]]></correctanswer>
      <incorrectanswer><![CDATA[Actually, patients taking <i>duet</i>act had an additional 1.6 percentage point mean reduction in A1C levels compared with those on a sulfonylurea alone.*<FONT FACE="GG Superscript">1,2</FONT> A1C reductions were sustained out to 2 years.<FONT FACE="GG Superscript">3</FONT>]]></incorrectanswer>
      <annotations>
        <notation id="1" title="footnote"><![CDATA[*Results from a 24-week, double-blind, randomized, multicenter study. Baseline A1C for 30 mg QD: 9.8%, n=351.]]></notation>
        <notation id="2" title="references"><![CDATA[<b>1.</b> Data on File, Takeda Pharmaceuticals North America, Inc. <b>2.</b> <i>Duet</i>act package insert, Takeda Pharmaceuticals America, Inc. <b>3.</b> Charbonnel B, Schernthaner G, Brunetti P, et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. <i>Diabetologia.</i> 2005;<br>48:1093-1104.]]></notation>
        <notation id="3" title="fairbalance"><![CDATA[Management of type 2 diabetes should also include nutritional counseling, weight reduction as needed, and exercise.<br><br>Please see Important Safety Information, <b>including boxed warnings</b>, by clicking on the Safety button in the Menu.]]></notation>
        <notation id="4" title="indication"><![CDATA[<i>Duet</i>act is indicated with diet and exercise as a once-daily combination therapy to improve glycemic control in patients with type 2 diabetes who are already treated with a combination of pioglitazone and a sulfonylurea or whose diabetes is not adequately controlled with a sulfonylurea alone, or for those patients who have initially responded to pioglitazone alone and require additional glycemic control.<FONT FACE="GG Superscript">2</FONT>]]></notation>
      </annotations>
      <complexityfactor>1</complexityfactor>
    </question>
    <question id="3" qid="15">
      <copy><![CDATA[How long were A1C reductions sustained with ACTOS plus metformin in PROactive?]]></copy>
      <answer correct="0"><![CDATA[Less than 6 months]]></answer>
      <answer correct="0"><![CDATA[1 year]]></answer>
      <answer correct="1"><![CDATA[Beyond 2.5 years]]></answer>
	  <drug><![CDATA[ACTOSPLUSMET]]></drug>
      <graphic></graphic>
      <correctanswer><![CDATA[Way to go! Patients taking ACTOS plus metformin sustained their A1C levels for more than 2.5 years in PROactive.<FONT FACE="GG Superscript">1,2</FONT>]]></correctanswer>
      <incorrectanswer><![CDATA[It's actually longer; patients taking ACTOS plus metformin sustained their A1C levels for more than 2.5 years in PROactive.<FONT FACE="GG Superscript">1,2</FONT>]]></incorrectanswer>
      <annotations>
        <notation id="1" title="footnote"><![CDATA[]]></notation>
        <notation id="2" title="references"><![CDATA[<b>1.</b> Data on file, Takeda Pharmaceuticals North America, Inc. <b>2.</b> Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A, on behalf of the PROactive Study Group. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5,238 patients. <i>Diabetes Care.</i> 2004;27:1647-1653. <b>3.</b> ACTOS package insert. Takeda Pharmaceuticals America, Inc.]]></notation>
        <notation id="3" title="fairbalance"><![CDATA[Management of type 2 diabetes should also include nutritional counseling, weight reduction as needed, and exercise.<br><br>Please see Important Safety Information, <b>including boxed warnings</b>, by clicking on the Safety button in the Menu.]]></notation>
        <notation id="4" title="indication"><![CDATA[ACTOS is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. ACTOS is approved for use as monotherapy and in combination with sulfonylureas, metformin, or insulin when diet and exercise plus the single agent do not result in adequate glycemic control.<FONT FACE="GG Superscript">3</FONT>]]></notation>
      </annotations>
      <complexityfactor>1</complexityfactor>
    </question>
  </category>
  <category id="5" title="DYSLIPIDEMIA">
    <question id="1" qid="17">
      <copy><![CDATA[How much did mean triglyceride levels drop in patients with type 2 diabetes after 2 years of ACTOS <i>QD</i> monotherapy?]]></copy>
      <answer correct="0"><![CDATA[11%]]></answer>
      <answer correct="1"><![CDATA[21%]]></answer>
      <answer correct="0"><![CDATA[31%]]></answer>
	  <drug><![CDATA[ACTOS]]></drug>
      <graphic>q17_image_01.jpg</graphic>
      <correctanswer><![CDATA[You're right! In a 2-year clinical trial, patients taking ACTOS 30 or 45 mg QD monotherapy had a 21% mean reduction in their triglyceride levels from baseline.* Mean baseline triglyceride was 211.0 mg/dL.<FONT FACE="GG Superscript">1</FONT> The ADA recommends triglycerides measure &lt;150 mg/dL.<FONT FACE="GG Superscript">2</FONT>]]></correctanswer>
      <incorrectanswer><![CDATA[Not quite. In a 2-year clinical trial, patients taking ACTOS 30 or 45 mg QD monotherapy had a 21% mean reduction in their triglyceride levels from baseline.* Mean baseline triglyceride was 211.0 mg/dL.<FONT FACE="GG Superscript">1</FONT> The ADA recommends triglycerides measure &lt;150 mg/dL.<FONT FACE="GG Superscript">2</FONT>]]></incorrectanswer>
      <annotations>
        <notation id="1" title="footnote"><![CDATA[*Results from a 104-week, double-blind, randomized, double-dummy, multicenter, parallel-group study using ACTOS 30 or 45 mg QD monotherapy. Completer analysis, n=147. Mean change at endpoint statistically significant vs baseline at <i>P</i>&lt;0.0001. Baseline LDL-C:<br>126.0 mg/dL; total cholesterol: 207.6 mg/dL.]]></notation>
        <notation id="2" title="references"><![CDATA[<b>1.</b> Data on file, Takeda Pharmaceuticals North America, Inc. <b>2.</b> American Diabetes Association. Standards of medical care in diabetes−2008. <i>Diabetes Care.</i> 2008;31(suppl 1):S12-S54.<br><b>3.</b> ACTOS package insert, Takeda Pharmaceuticals America, Inc. ]]></notation>
        <notation id="3" title="fairbalance"><![CDATA[While ACTOS may confer some lipid benefits, ACTOS is not indicated to treat lipid disorders and should not be used as a substitute for lipid-lowering therapy.<br><br>The effects of these lipid changes on morbidity and mortality have not been determined.<br><br>Management of type 2 diabetes should also include nutritional counseling, weight reduction as needed, and exercise.<br><br>Please see Important Safety Information, <b>including boxed warnings</b>, by clicking on the Safety button in the Menu.]]></notation>
        <notation id="4" title="indication"><![CDATA[ACTOS is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. ACTOS is approved for use as monotherapy and in combination with sulfonylureas, metformin, or insulin when diet and exercise plus the single agent do not result in adequate glycemic control.<FONT FACE="GG Superscript">3</FONT>]]></notation>
      </annotations>
      <complexityfactor>1</complexityfactor>
    </question>
    <question id="2" qid="18">
      <copy><![CDATA[What effect does ACTOS <i>QD</i> monotherapy have on HDL-C levels?]]></copy>
      <answer correct="0"><![CDATA[Decreases HDL-C]]></answer>
      <answer correct="1"><![CDATA[Increases HDL-C]]></answer>
      <answer correct="0"><![CDATA[Provides no consistent mean change]]></answer>
	  <drug><![CDATA[ACTOS]]></drug>
      <graphic>q18_image_01.jpg</graphic>
      <correctanswer><![CDATA[You know your stuff! ACTOS has been shown to increase HDL-C. In a 2-year clinical trial, patients taking ACTOS 30 or 45 mg QD monotherapy had a mean 33% increase in their HDL-C levels compared with baseline.*<FONT FACE="GG Superscript">1</FONT> Such improvements are worth noting, especially because a recent study found that nearly half (49.5%) of primary care patients with type 2 diabetes had low HDL-C.<FONT FACE="GG Superscript">2</FONT>]]></correctanswer>
      <incorrectanswer><![CDATA[Actually, ACTOS has been shown to increase HDL-C. In a 2-year clinical trial, patients taking ACTOS 30 or 45 mg QD monotherapy had a mean 33% increase in their HDL-C levels compared with baseline.*<FONT FACE="GG Superscript">1</FONT> Such improvements are worth noting, especially because a recent study found that nearly half (49.5%) of primary care patients with type 2 diabetes had low HDL-C.<FONT FACE="GG Superscript">2</FONT>]]></incorrectanswer>
      <annotations>
        <notation id="1" title="footnote"><![CDATA[*Results from a 104-week, double-blind, randomized, double-dummy, multicenter, parallel-group study using ACTOS 30 or 45 mg QD monotherapy. Completer analysis, n=147. Mean change at endpoint statistically significant vs baseline at <i>P</i>&lt;0.0001. Baseline LDL-C:<br>126.0 mg/dL; total cholesterol: 207.6 mg/dL.]]></notation>
        <notation id="2" title="references"><![CDATA[<b>1.</b> Data on file, Takeda Pharmaceuticals North America, Inc. <b>2.</b> Grant RW, Meigs JB. Prevalence and treatment of low HDL cholesterol among primary care patients with type 2 diabetes: an unmet challenge for cardiovascular risk reduction. <i>Diabetes Care.</i> 2007;30:479-484. <b>3.</b> ACTOS package insert, Takeda Pharmaceuticals America, Inc.]]></notation>
        <notation id="3" title="fairbalance"><![CDATA[While ACTOS may confer some lipid benefits, ACTOS is not indicated to treat lipid disorders and should not be used as a substitute for lipid-lowering therapy.<br><br>The effects of these lipid changes on morbidity and mortality have not been determined.<br><br>Management of type 2 diabetes should also include nutritional counseling, weight reduction as needed, and exercise.<br><br>Please see Important Safety Information, <b>including boxed warnings</b>, by clicking on the Safety button in the Menu.]]></notation>
        <notation id="4" title="indication"><![CDATA[ACTOS is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. ACTOS is approved for use as monotherapy and in combination with sulfonylureas, metformin, or insulin when diet and exercise plus the single agent do not result in adequate glycemic control.<FONT FACE="GG Superscript">3</FONT>]]></notation>
      </annotations>
      <complexityfactor>1</complexityfactor>
    </question>
    <question id="3" qid="20">
      <copy><![CDATA[What is the American Diabetes Association (ADA)-recommended HDL-C level for women?]]></copy>
      <answer correct="1"><![CDATA[>50 mg/dL]]></answer>
      <answer correct="0"><![CDATA[&lt;50 mg/dL]]></answer>
      <answer correct="0"><![CDATA[>40 mg/dL]]></answer>
	  <drug><![CDATA[ACTOS]]></drug>
      <graphic></graphic>
      <correctanswer><![CDATA[Way to go! The ADA guidelines recommend that women with type 2 diabetes achieve an HDL-C level of >50 mg/dL. HDL-C levels in men should be >40 mg/dL.<FONT FACE="GG Superscript">1</FONT>]]></correctanswer>
      <incorrectanswer><![CDATA[Not exactly! The ADA guidelines recommend that women with type 2 diabetes achieve an HDL-C level of >50 mg/dL. HDL-C levels in men should be >40 mg/dL.<FONT FACE="GG Superscript">1</FONT>]]></incorrectanswer>
      <annotations>
        <notation id="1" title="footnote"><![CDATA[]]></notation>
        <notation id="2" title="references"><![CDATA[<b>1.</b> American Diabetes Association. Standards of medical care in diabetes−2008. <i>Diabetes Care.</i> 2008;31(suppl 1):S12-S54. <b>2.</b> ACTOS package insert, Takeda Pharmaceuticals America, Inc.]]></notation>
        <notation id="3" title="fairbalance"><![CDATA[While ACTOS may confer some lipid benefits, ACTOS is not indicated to treat lipid disorders and should not be used as a substitute for lipid-lowering therapy.<br><br>The effects of these lipid changes on morbidity and mortality have not been determined.<br><br>Management of type 2 diabetes should also include nutritional counseling, weight reduction as needed, and exercise.<br><br>Please see Important Safety Information, <b>including boxed warnings</b>, by clicking on the Safety button in the Menu.]]></notation>
        <notation id="4" title="indication"><![CDATA[ACTOS is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. ACTOS is approved for use as monotherapy and in combination with sulfonylureas, metformin, or insulin when diet and exercise plus the single agent do not result in adequate glycemic control.<FONT FACE="GG Superscript">2</FONT>]]></notation>
      </annotations>
      <complexityfactor>1</complexityfactor>
    </question>
  </category>
  <category id="6" title="Compliance">	
    <question id="1" qid="21">
      <copy><![CDATA[Among newly treated patients with type 2 diabetes, approximately what percentage fail to adhere to their treatment regimen?]]></copy>
      <answer correct="0"><![CDATA[36%]]></answer>
      <answer correct="1"><![CDATA[46%]]></answer>
      <answer correct="0"><![CDATA[56%]]></answer>
	  <drug><![CDATA[ACTOS]]></drug>
      <graphic></graphic>
      <correctanswer><![CDATA[That's right! 46.2% of patients being treated for type 2 diabetes failed to comply with their treatment, according to findings from a retrospective cohort study of 6,090 adult patients with employer-sponsored medical insurance.<FONT FACE="GG Superscript">1</FONT>]]></correctanswer>
      <incorrectanswer><![CDATA[Not quite. 46.2% of patients being treated for type 2 diabetes failed to comply with their treatment, according to findings from a retrospective cohort study of 6,090 adult patients with employer-sponsored medical insurance.<FONT FACE="GG Superscript">1</FONT>]]></incorrectanswer>
      <annotations>
        <notation id="1" title="footnote"><![CDATA[]]></notation>
        <notation id="2" title="references"><![CDATA[<b>1.</b> Hertz RP, Unger AN, Lustik MB. Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance. <i>Clin Ther.</i> 2005;27:1064-1073. <b>2.</b> ACTOS package insert, Takeda Pharmaceuticals America, Inc.]]></notation>
        <notation id="3" title="fairbalance"><![CDATA[Management of type 2 diabetes should also include nutritional counseling, weight reduction as needed, and exercise.<br><br>Please see Important Safety Information, <b>including boxed warnings</b>, by clicking on the Safety button in the Menu.]]></notation>
        <notation id="4" title="indication"><![CDATA[ACTOS is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. ACTOS is approved for use as monotherapy and in combination with sulfonylureas, metformin, or insulin when diet and exercise plus the single agent do not result in adequate glycemic control.<FONT FACE="GG Superscript">2</FONT>]]></notation>
      </annotations>
      <complexityfactor>1</complexityfactor>
    </question>
    <question id="2" qid="22">
      <copy><![CDATA[Compared with a loose-dose combination medication, what effect does a fixed-dose combination have on medication persistence?]]></copy>
      <answer correct="1"><![CDATA[Increases the median number of days patients persist with their medication]]></answer>
      <answer correct="0"><![CDATA[Decreases the median number of days patients persist with their medication]]></answer>
      <answer correct="0"><![CDATA[Has no effect]]></answer>
	  <drug><![CDATA[ACTOS]]></drug>
      <graphic>q22_image_01.jpg</graphic>
      <correctanswer><![CDATA[You're right! Fixed-dose combination medication increases the median number of days patients persist taking their medication: 155 days vs 90 days with a loose-dose combination.<FONT FACE="GG Superscript">1</FONT>]]></correctanswer>
      <incorrectanswer><![CDATA[That's not correct. Fixed-dose combination medication increases the median number of days patients persist taking their medication: 155 days vs 90 days with a loose-dose combination.<FONT FACE="GG Superscript">1</FONT>]]></incorrectanswer>
      <annotations>
        <notation id="1" title="footnote"><![CDATA[]]></notation>
        <notation id="2" title="references"><![CDATA[<b>1.</b> Data on file, Takeda Pharmaceuticals North America, Inc. <b>2.</b> ACTOS package insert, Takeda Pharmaceuticals America, Inc.]]></notation>
        <notation id="3" title="fairbalance"><![CDATA[Management of type 2 diabetes should also include nutritional counseling, weight reduction as needed, and exercise.<br><br>Please see Important Safety Information, <b>including boxed warnings</b>, by clicking on the Safety button in the Menu.]]></notation>
        <notation id="4" title="indication"><![CDATA[ACTOS is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. ACTOS is approved for use as monotherapy and in combination with sulfonylureas, metformin, or insulin when diet and exercise plus the single agent do not result in adequate glycemic control.<FONT FACE="GG Superscript">2</FONT>]]></notation>
      </annotations>
      <complexityfactor>1</complexityfactor>
    </question>
    <question id="3" qid="23">
      <copy><![CDATA[How many patients with diabetes report cutting back<br>on their medications?]]></copy>
      <answer correct="0"><![CDATA[17%]]></answer>
      <answer correct="0"><![CDATA[18%]]></answer>
      <answer correct="1"><![CDATA[19%]]></answer>
	  <drug><![CDATA[ACTOS]]></drug>
      <graphic></graphic>
      <correctanswer><![CDATA[That's right! In a survey of patients with diabetes, 19% reported cutting back on medications.<FONT FACE="GG Superscript">1</FONT> Compliance problems result in higher A1C levels, more symptoms, and poorer mental and physical functioning.<FONT FACE="GG Superscript">2</FONT>]]></correctanswer>
      <incorrectanswer><![CDATA[Not quite. In a survey of patients with diabetes, 19% reported cutting back on medications.<FONT FACE="GG Superscript">1</FONT> Compliance problems result in higher A1C levels, more symptoms, and poorer mental and physical functioning.<FONT FACE="GG Superscript">2</FONT>]]></incorrectanswer>
      <annotations>
        <notation id="1" title="footnote"><![CDATA[]]></notation>
        <notation id="2" title="references"><![CDATA[<b>1.</b> Piette JD, Heisler M, Wagner TH. Problems paying out-of-pocket medication costs among older adults with diabetes. <i>Diabetes Care.</i> 2004;27:384-391. <b>2.</b> Piette JD, Wagner TH, Potter MB, Schillinger D. Health insurance status, cost-related medication underuse, and outcomes among diabetes patients in three systems of care. <i>Med Care.</i> 2004;42:102-109. <b>3.</b> ACTOS package insert, Takeda Pharmaceuticals America, Inc.]]></notation>
        <notation id="3" title="fairbalance"><![CDATA[Management of type 2 diabetes should also include nutritional counseling, weight reduction as needed, and exercise.<br><br>Please see Important Safety Information, <b>including boxed warnings</b>, by clicking on the Safety button in the Menu.]]></notation>
        <notation id="4" title="indication"><![CDATA[ACTOS is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. ACTOS is approved for use as monotherapy and in combination with sulfonylureas, metformin, or insulin when diet and exercise plus the single agent do not result in adequate glycemic control.<FONT FACE="GG Superscript">3</FONT>]]></notation>
      </annotations>
      <complexityfactor>1</complexityfactor>
    </question>		
  </category>
  <category id="7" title="Miscellaneous">
    <question id="1" qid="24">
      <copy><![CDATA[Which type of diabetes is more common in the United States?]]></copy>
      <answer correct="0"><![CDATA[Type 1]]></answer>
      <answer correct="1"><![CDATA[Type 2]]></answer>
	  <drug><![CDATA[ACTOS]]></drug>
      <graphic></graphic>
      <correctanswer><![CDATA[You know your stuff! Only 5%−10% of Americans diagnosed with diabetes have type 1 diabetes, making type 2 diabetes more common.<FONT FACE="GG Superscript">1</FONT>]]></correctanswer>
      <incorrectanswer><![CDATA[Not quite. Only 5%−10% of Americans diagnosed with diabetes have type 1 diabetes, making type 2 diabetes more common.<FONT FACE="GG Superscript">1</FONT>]]></incorrectanswer>
      <annotations>
        <notation id="1" title="footnote"><![CDATA[]]></notation>
        <notation id="2" title="references"><![CDATA[<b>1.</b> American Diabetes Association website. All about diabetes. Available at: http://www.diabetes.org/about-diabetes.jsp. Accessed May 23, 2008. <b>2.</b> ACTOS package insert, Takeda Pharmaceuticals America, Inc.]]></notation>
        <notation id="3" title="fairbalance"><![CDATA[Management of type 2 diabetes should also include nutritional counseling, weight reduction as needed, and exercise.<br><br>Please see Important Safety Information, <b>including boxed warnings</b>, by clicking on the Safety button in the Menu.]]></notation>
        <notation id="4" title="indication"><![CDATA[ACTOS is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. ACTOS is approved for use as monotherapy and in combination with sulfonylureas, metformin, or insulin when diet and exercise plus the single agent do not result in adequate glycemic control.<FONT FACE="GG Superscript">2</FONT>]]></notation>
      </annotations>
      <complexityfactor>1</complexityfactor>
    </question>
    <question id="2" qid="25">
      <copy><![CDATA[Approximately how many Americans have diabetes, according to the American Diabetes Association?]]></copy>
      <answer correct="0"><![CDATA[41 million]]></answer>
	  <answer correct="0"><![CDATA[31 million]]></answer>
      <answer correct="1"><![CDATA[21 million]]></answer>
	  <drug><![CDATA[ACTOS]]></drug>
      <graphic></graphic>
      <correctanswer><![CDATA[You know your stats! 20.8 million Americans have diabetes.<FONT FACE="GG Superscript">1</FONT>]]></correctanswer>
      <incorrectanswer><![CDATA[Not even close. 20.8 million Americans have diabetes.<FONT FACE="GG Superscript">1</FONT>]]></incorrectanswer>
      <annotations>
        <notation id="1" title="footnote"><![CDATA[]]></notation>
        <notation id="2" title="references"><![CDATA[<b>1.</b> American Diabetes Association website. All about diabetes. Available at: http://www.diabetes.org/about-diabetes.jsp. Accessed May 23, 2008. <b>2.</b> ACTOS<br>package insert, Takeda Pharmaceuticals America, Inc.]]></notation>
        <notation id="3" title="fairbalance"><![CDATA[Management of type 2 diabetes should also include nutritional counseling, weight reduction as needed, and exercise.<br><br>Please see Important Safety Information, <b>including boxed warnings</b>, by clicking on the Safety button in the Menu.]]></notation>
        <notation id="4" title="indication"><![CDATA[ACTOS is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. ACTOS is approved for use as monotherapy and in combination with sulfonylureas, metformin, or insulin when diet and exercise plus the single agent do not result in adequate glycemic control.<FONT FACE="GG Superscript">2</FONT>]]></notation>
      </annotations>
      <complexityfactor>1</complexityfactor>
    </question>
    <question id="3" qid="26">
      <copy><![CDATA[ACTOS has how many years of clinical experience?]]></copy>
      <answer correct="0"><![CDATA[12 years]]></answer>
	  <answer correct="1"><![CDATA[9 years]]></answer>
      <answer correct="0"><![CDATA[6 years]]></answer>
	  <drug><![CDATA[ACTOS]]></drug>
      <graphic></graphic>
      <correctanswer><![CDATA[You've got a great memory! Launched in 1999, ACTOS has more than 9 years of clinical experience.<FONT FACE="GG Superscript">1</FONT>]]></correctanswer>
      <incorrectanswer><![CDATA[Close, but ACTOS actually has more than 9 years of clinical experience.<FONT FACE="GG Superscript">1</FONT>]]></incorrectanswer>
      <annotations>
        <notation id="1" title="footnote"><![CDATA[]]></notation>
        <notation id="2" title="references"><![CDATA[<b>1.</b> Data on file, Takeda Pharmaceuticals North America, Inc. <b>2.</b> ACTOS package insert, Takeda Pharmaceuticals America, Inc. ]]></notation>
        <notation id="3" title="fairbalance"><![CDATA[Management of type 2 diabetes should also include nutritional counseling, weight reduction as needed, and exercise.<br><br>Please see Important Safety Information, <b>including boxed warnings</b>, by clicking on the Safety button in the Menu.]]></notation>
        <notation id="4" title="indication"><![CDATA[ACTOS is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. ACTOS is approved for use as monotherapy and in combination with sulfonylureas, metformin, or insulin when diet and exercise plus the single agent do not result in adequate glycemic control.<FONT FACE="GG Superscript">2</FONT>]]></notation>
      </annotations>
      <complexityfactor>1</complexityfactor>
    </question>
  </category>
  <category id="8" title="Miscellaneous_2">	
    <question id="1" qid="28">
      <copy><![CDATA[More than 82 million ACTOS prescriptions have been written.]]></copy>
      <answer correct="1"><![CDATA[True]]></answer>
	  <answer correct="0"><![CDATA[False]]></answer>
	  <drug><![CDATA[ACTOS]]></drug>
      <graphic></graphic>
      <correctanswer><![CDATA[That's correct! Physicians have written more than 82 million prescriptions for more than 8 million patients since 1999, according to IMS Health, NPA™, April 25, 2008 data.<FONT FACE="GG Superscript">1</FONT>]]></correctanswer>
      <incorrectanswer><![CDATA[Actually, physicians have written more than 82 million prescriptions for more than 8 million patients since 1999, according to IMS Health, NPA™, April 25, 2008 data.<FONT FACE="GG Superscript">1</FONT>]]></incorrectanswer>
      <annotations>
        <notation id="1" title="footnote"><![CDATA[]]></notation>
        <notation id="2" title="references"><![CDATA[<b>1.</b> Data on file, Takeda Pharmaceuticals North America, Inc. <b>2.</b> ACTOS package insert, Takeda Pharmaceuticals America, Inc. ]]></notation>
        <notation id="3" title="fairbalance"><![CDATA[Management of type 2 diabetes should also include nutritional counseling, weight reduction as needed, and exercise.<br><br>Please see Important Safety Information, <b>including boxed warnings</b>, by clicking on the Safety button in the Menu.]]></notation>
        <notation id="4" title="indication"><![CDATA[ACTOS is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. ACTOS is approved for use as monotherapy and in combination with sulfonylureas, metformin, or insulin when diet and exercise plus the single agent do not result in adequate glycemic control.<FONT FACE="GG Superscript">2</FONT>]]></notation>
      </annotations>
      <complexityfactor>1</complexityfactor>
    </question>
	<question id="2" qid="29">
      <copy><![CDATA[The Patient Assistance Program gives patients who would otherwise find it financially difficult to receive type 2 diabetes treatment access to a free year of ACTOS therapy.]]></copy>
      <answer correct="1"><![CDATA[True]]></answer>
	  <answer correct="0"><![CDATA[False]]></answer>
	  <drug><![CDATA[ACTOS]]></drug>
      <graphic></graphic>
      <correctanswer><![CDATA[Yes! The Patient Assistance Program does give patients who would otherwise find it financially difficult to receive type 2 diabetes treatment access to a free year of ACTOS therapy. To find out more about this program, ask your ACTOS representative or call 1-800-830-9159.]]></correctanswer>
      <incorrectanswer><![CDATA[Actually, the Patient Assistance Program does give patients who would otherwise find it financially difficult to receive type 2 diabetes treatment access to a free year of ACTOS therapy. To find out more about this program, ask your ACTOS representative or call 1-800-830-9159.]]></incorrectanswer>
      <annotations>
        <notation id="1" title="footnote"><![CDATA[]]></notation>
        <notation id="2" title="references"><![CDATA[<b>1.</b> ACTOS package insert, Takeda Pharmaceuticals America, Inc. ]]></notation>
        <notation id="3" title="fairbalance"><![CDATA[Management of type 2 diabetes should also include nutritional counseling, weight reduction as needed, and exercise.<br><br>Please see Important Safety Information, <b>including boxed warnings</b>, by clicking on the Safety button in the Menu.]]></notation>
        <notation id="4" title="indication"><![CDATA[ACTOS is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. ACTOS is approved for use as monotherapy and in combination with sulfonylureas, metformin, or insulin when diet and exercise plus the single agent do not result in adequate glycemic control.<FONT FACE="GG Superscript">1</FONT>]]></notation>
      </annotations>
      <complexityfactor>1</complexityfactor>
    </question>
	<question id="3" qid="30">
      <copy><![CDATA[ACTOS <i>QD</i> is available in which of the following dosage strengths?]]></copy>
      <answer correct="0"><![CDATA[15 mg]]></answer>
	  <answer correct="0"><![CDATA[30 mg]]></answer>
	  <answer correct="0"><![CDATA[45 mg]]></answer>
	  <answer correct="1"><![CDATA[All of the above]]></answer>
	  <drug><![CDATA[ACTOS]]></drug>
      <graphic></graphic>
      <correctanswer><![CDATA[You're right! ACTOS <i>QD</i> is available in 15-, 30-, and 45-mg tablets. ACTOS can be taken without regard to meals.<FONT FACE="GG Superscript">1</FONT>]]></correctanswer>
      <incorrectanswer><![CDATA[Actually, ACTOS <i>QD</i> is available in 15-, 30-, and 45-mg tablets. ACTOS can be taken without regard to meals.<FONT FACE="GG Superscript">1</FONT>]]></incorrectanswer>
      <annotations>
        <notation id="1" title="footnote"><![CDATA[]]></notation>
        <notation id="2" title="references"><![CDATA[<b>1.</b> ACTOS package insert, Takeda Pharmaceuticals America, Inc. ]]></notation>
        <notation id="3" title="fairbalance"><![CDATA[Management of type 2 diabetes should also include nutritional counseling, weight reduction as needed, and exercise.<br><br>Please see Important Safety Information, <b>including boxed warnings</b>, by clicking on the Safety button in the Menu.]]></notation>
        <notation id="4" title="indication"><![CDATA[ACTOS is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. ACTOS is approved for use as monotherapy and in combination with sulfonylureas, metformin, or insulin when diet and exercise plus the single agent do not result in adequate glycemic control.<FONT FACE="GG Superscript">1</FONT>]]></notation>
      </annotations>
      <complexityfactor>1</complexityfactor>
    </question>		
  </category>
  <category id="9" title="Tie-Breaker">
    <question id="1" qid="9">
      <copy><![CDATA[What is/are the target A1C goal(s) for patients with type 2 diabetes, according to the American Diabetes Association (ADA)?]]></copy>
      <answer correct="0"><![CDATA[&lt;6.0%]]></answer>
      <answer correct="0"><![CDATA[≤6.5%]]></answer>
      <answer correct="0"><![CDATA[&lt;7.0%]]></answer>
      <answer correct="1"><![CDATA[Both a & c]]></answer>
	  <drug><![CDATA[ACTOS]]></drug>
      <graphic>q9_image_01.jpg</graphic>
      <correctanswer><![CDATA[You know your ADA guidelines! The ADA recommends that all patients with type 2 diabetes achieve an A1C goal of &lt;7.0%. A more stringent goal of &lt;6% is recommended for selected individual patients without increasing their risk of hypoglycemia.<FONT FACE="GG Superscript">1</FONT>]]></correctanswer>
      <incorrectanswer><![CDATA[Actually, the ADA recommends that all patients with type 2 diabetes achieve an A1C goal of &lt;7.0%. A more stringent goal of &lt;6% is recommended for selected individual patients without increasing their risk of hypoglycemia.<FONT FACE="GG Superscript">1</FONT>]]></incorrectanswer>
      <annotations>
        <notation id="1" title="footnote"><![CDATA[]]></notation>
        <notation id="2" title="references"><![CDATA[<b>1.</b> American Diabetes Association. Standards of medical care in diabetes−2008. <i>Diabetes Care.</i> 2008;31(suppl 1):S12-S54. <b>2.</b> Jellinger PS, Davidson JA, Blonde L, et al. Road map to achieve glycemic goals: naïve to therapy (type 2). American Association of Clinical Endocrinologists website. Available at: http://www.aace.com/meetings/consensus/odimplementation/roadmap.pdf.<br>Accessed June 2, 2008. <b>3.</b> ACTOS package insert, Takeda Pharmaceuticals America, Inc.]]></notation>
        <notation id="3" title="fairbalance"><![CDATA[Management of type 2 diabetes should also include nutritional counseling, weight reduction as needed, and exercise.<br><br>Please see Important Safety Information, <b>including boxed warnings</b>, by clicking on the Safety button in the Menu.]]></notation>
        <notation id="4" title="indication"><![CDATA[ACTOS is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. ACTOS is approved for use as monotherapy and in combination with sulfonylureas, metformin, or insulin when diet and exercise plus the single agent do not result in adequate glycemic control.<FONT FACE="GG Superscript">3</FONT>]]></notation>
      </annotations>
      <complexityfactor>1</complexityfactor>
    </question>
    <question id="2" qid="16">
      <copy><![CDATA[According to the American Association of Clinical Endocrinologists (AACE) recommendations, at what A1C level(s) should combination therapy be initiated?]]></copy>
      <answer correct="0"><![CDATA[6%−7%]]></answer>
      <answer correct="0"><![CDATA[7%−8%]]></answer>
      <answer correct="0"><![CDATA[8%−10%]]></answer>
      <answer correct="1"><![CDATA[Both b and c]]></answer>
	  <drug><![CDATA[ACTOS]]></drug>
      <graphic>q16_image_01.jpg</graphic>
      <correctanswer><![CDATA[Yes! The AACE recommends that combination therapy first be initiated when patients' A1C levels are between 7%−8%. Combination therapy should also be initiated and intensified as A1C levels rise to 8% and above.<FONT FACE="GG Superscript">1</FONT>]]></correctanswer>
      <incorrectanswer><![CDATA[Actually, the AACE recommends that combination therapy first be initiated when patients' A1C levels are between 7%−8%. Combination therapy should also be initiated and intensified as A1C levels rise to 8% and above.<FONT FACE="GG Superscript">1</FONT>]]></incorrectanswer>
      <annotations>
        <notation id="1" title="footnote"><![CDATA[]]></notation>
        <notation id="2" title="references"><![CDATA[<b>1.</b> AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. <i>Endocr Pract.</i> 2007;13(suppl 1):3-68. <b>2.</b> ACTOS package insert, Takeda Pharmaceuticals America, Inc.]]></notation>
        <notation id="3" title="fairbalance"><![CDATA[Management of type 2 diabetes should also include nutritional counseling, weight reduction as needed, and exercise.<br><br>Please see Important Safety Information, <b>including boxed warnings</b>, by clicking on the Safety button in the Menu.]]></notation>
        <notation id="4" title="indication"><![CDATA[ACTOS is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. ACTOS is approved for use as monotherapy and in combination with sulfonylureas, metformin, or insulin when diet and exercise plus the single agent do not result in adequate glycemic control.<FONT FACE="GG Superscript">2</FONT>]]></notation>
      </annotations>
      <complexityfactor>1</complexityfactor>
    </question>
    <question id="3" qid="19">
      <copy><![CDATA[ACTOS has not been shown to improve the Total-C/HDL-C ratio.]]></copy>
      <answer correct="0"><![CDATA[True]]></answer>
      <answer correct="1"><![CDATA[False]]></answer>
	  <drug><![CDATA[ACTOS]]></drug>
      <graphic></graphic>
      <correctanswer><![CDATA[Yes! ACTOS has been shown to improve the Total-C/HDL-C ratio.<FONT FACE="GG Superscript">1</FONT> ACTOS has shown no consistent mean changes in LDL-C or Total-C levels.<FONT FACE="GG Superscript">2</FONT>]]></correctanswer>
      <incorrectanswer><![CDATA[In fact, ACTOS has been shown to improve the Total-C/HDL-C ratio.<FONT FACE="GG Superscript">1</FONT> ACTOS has shown no consistent mean changes in LDL-C or Total-C levels.<FONT FACE="GG Superscript">2</FONT>]]></incorrectanswer>
      <annotations>
        <notation id="1" title="footnote"><![CDATA[]]></notation>
        <notation id="2" title="references"><![CDATA[<b>1.</b> Data on file, Takeda Pharmaceuticals North America, Inc. <b>2.</b> ACTOS package insert, Takeda Pharmaceuticals America, Inc.]]></notation>
        <notation id="3" title="fairbalance"><![CDATA[While ACTOS may confer some lipid benefits, ACTOS is not indicated to treat lipid disorders and should not be used as a substitute for lipid-lowering therapy.<br><br>The effects of these lipid changes on morbidity and mortality have not been determined.<br><br>Management of type 2 diabetes should also include nutritional counseling, weight reduction as needed, and exercise.<br><br>Please see Important Safety Information, <b>including boxed warnings</b>, by clicking on the Safety button in the Menu.]]></notation>
        <notation id="4" title="indication"><![CDATA[ACTOS is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. ACTOS is approved for use as monotherapy and in combination with sulfonylureas, metformin, or insulin when diet and exercise plus the single agent do not result in adequate glycemic control.<FONT FACE="GG Superscript">2</FONT>]]></notation>
      </annotations>
      <complexityfactor>1</complexityfactor>
    </question>
    <question id="4" qid="27">
      <copy><![CDATA[ACTOS has been prescribed to approximately how many patients?]]></copy>
      <answer correct="0"><![CDATA[12 million]]></answer>
	  <answer correct="0"><![CDATA[10 million]]></answer>
      <answer correct="1"><![CDATA[8 million]]></answer>
	  <drug><![CDATA[ACTOS]]></drug>
      <graphic></graphic>
      <correctanswer><![CDATA[You're right! Since entering the marketplace in 1999, ACTOS has been prescribed to more than 8 million patients.<FONT FACE="GG Superscript">1</FONT>]]></correctanswer>
      <incorrectanswer><![CDATA[Not quite. Since entering the marketplace in 1999, ACTOS has been prescribed to more than 8 million patients.<FONT FACE="GG Superscript">1</FONT>]]></incorrectanswer>
      <annotations>
        <notation id="1" title="footnote"><![CDATA[]]></notation>
        <notation id="2" title="references"><![CDATA[<b>1.</b> Data on file, Takeda Pharmaceuticals North America, Inc. <b>2.</b> ACTOS package insert, Takeda Pharmaceuticals America, Inc. ]]></notation>
        <notation id="3" title="fairbalance"><![CDATA[Management of type 2 diabetes should also include nutritional counseling, weight reduction as needed, and exercise.<br><br>Please see Important Safety Information, <b>including boxed warnings</b>, by clicking on the Safety button in the Menu.]]></notation>
        <notation id="4" title="indication"><![CDATA[ACTOS is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. ACTOS is approved for use as monotherapy and in combination with sulfonylureas, metformin, or insulin when diet and exercise plus the single agent do not result in adequate glycemic control.<FONT FACE="GG Superscript">2</FONT>]]></notation>
      </annotations>
      <complexityfactor>1</complexityfactor>
    </question>	
  </category>
</quiz>